Verve
PublicVerve is now publicly traded
The data on this page reflects Verve's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 17, 2021
Last Round
M&A
Jun 17, 2025
Est. Valuation at Exit
$1.3B
Total Funding Raised
$1.95B
Company Overview
Verve Therapeutics (NAS: VERV) is a biotechnology company focused on developing innovative gene editing therapies to address cardiovascular disease through single-course treatments targeting key genetic factors.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Verve Comparables
Compare Verve with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Beijing Innova Medicine Technology Co., Ltd. | 62% | |
| Mammoth Biosciences | 60% | |
| Chroma Medicine | 53% |
Verve Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Jun 17, 2025 | ||||
| Follow-on Offering | Dec 1, 2023 | ||||
| Private Placement | Dec 1, 2023 | ||||
| IPO | Jun 17, 2021 | ||||
| Series B | Jan 19, 2021 | ||||
Series A Extension | Jun 11, 2020 |
Verve Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Jefferies | IPO |
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| GV | Series B, Series A Extension, Series A |
| Guggenheim Securities | IPO |
| F-Prime Capital | Series A Extension, Series A |
Verve Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access